金城医药：乳糖酸红霉素化学原料药上市申请获批准

Core Viewpoint - The company, Jincheng Pharmaceutical, has received approval from the National Medical Products Administration for its new chemical raw material drug, Lactulose Erythromycin, which is an antibiotic used for treating severe infectious diseases [1] Group 1 - Jincheng Pharmaceutical's wholly-owned subsidiary, Beijing Jincheng Tail Pharmaceutical Co., Ltd., has recently obtained the approval notice for the marketing application of Lactulose Erythromycin [1] - Lactulose Erythromycin is classified as a macrolide antibiotic [1] - The drug is intended for the treatment of serious infectious diseases [1]